Published in Science Direct – 2022

Collaborators: INSERM

Authors: Tangui Barré, Clémence Ramier, Camelia Protopopescu, Patrizia Carrieri, Lise Radoszycki

Lowering the effects of multiple sclerosis by using canabis-based products has been under studies for several years. A recent article explored the extent of medical cannabis use in people with multiple sclerosis (MS) in Canada (Santarossa et al., 2022). However, THC-based substances are still criminalized in several countries such as France. There is therefore, a need to explore the therapeutic use of cannabis-based products (CBP) by people living with MS in this country. Through an online survey, participants completed a self-administered online questionnaire that collected data on socio-demographic characteristics, type of CBP, route of administration, self-reported motives to use CBP, and perceived effectiveness.

Access to the abstract